GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK) announced its earnings results on Wednesday. The company reported GBX 46.50 earnings per share (EPS) for the quarter, Digital Look Earnings reports. The company had revenue of GBX 762.90 billion during the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%.

GSK Stock Performance

LON:GSK opened at GBX 1,935.50 on Thursday. The firm has a 50 day simple moving average of GBX 2,090.52 and a 200-day simple moving average of GBX 1,923.32. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. The firm has a market cap of £77.36 billion, a PE ratio of 13.94, a P/E/G ratio of 1.24 and a beta of 0.35. GSK has a 1-year low of GBX 1,288.61 and a 1-year high of GBX 2,282.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Insider buying: A senior insider, Wendy Becker, purchased 4,000 GSK shares at GBX 1,963, signaling management confidence in the shares. Insider Purchase Report
• Positive Sentiment: Q1 results beat: GSK reported GBX 46.50 EPS and GBX 762.9bn revenue; HIV and oncology products helped offset weakness in other medicines, supporting near-term earnings. Q1 Beat Coverage
• Positive Sentiment: Regulatory progress: GSK’s chronic hepatitis B candidate secured FDA priority review and management is targeting an October decision, which could be a material upside if approved. FDA Priority Review
• Positive Sentiment: Commercial momentum: Company commentary and coverage highlight first-quarter sales strength under new CEO Luke Miels, which investors may view as early validation of the turnaround plan. CEO Commentary
• Neutral Sentiment: Analyst stance: Deutsche Bank reaffirmed a “hold” rating with a GBX 1,900 target — suggests muted near-term upside per a major broker. Broker Note
• Neutral Sentiment: Marketing initiatives: GSK launched a shingles awareness campaign in Singapore — supportive for long-term brand/market penetration but not material to near-term earnings. Campaign
• Negative Sentiment: Legal provisions and litigation worries: Coverage notes legal provisions and a pre-trial setback for Tesaro (Jemperli dispute), which clouds near-term cash flow and creates headline risk. Legal Provisions Coverage
• Negative Sentiment: R&D/priorities cut: GSK walked away from a $100M option on Mersana’s STING ADC and paused its mRNA bird-flu program — these moves reduce near-term R&D optionality and may worry growth-focused investors. Program Pause Report
• Negative Sentiment: Business mix pressure: Commentary highlights that declines in older, general medicines are undermining GSK’s overhaul — a reminder that top-line mix shifts could keep margins and growth under pressure. Overhaul Concerns
• Negative Sentiment: Tesaro legal setback: A pre-trial blow in the Jemperli contract dispute with AnaptysBio raises potential litigation costs/uncertainty tied to the Tesaro unit. Tesaro Litigation

Insider Activity

In other news, insider Jonathan Symonds acquired 5,000 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was acquired at an average price of GBX 1,951 per share, with a total value of £97,550. Also, insider Wendy Becker acquired 4,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was purchased at an average cost of GBX 1,963 per share, with a total value of £78,520. In the last three months, insiders acquired 15,452 shares of company stock worth $32,135,952. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research report on Tuesday, April 14th. UBS Group restated a “neutral” rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Citigroup lifted their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 target price on shares of GSK in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of GBX 2,055.71.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.